What are the guideline sources, guidelines and references for Tardive dyskinesia ?
Guideline sources The following summarized guidelines for the management of tardive dyskinesia are prepared by our editorial team based on guidelines from the American Academy of Neurology (AAN 2013). 1 Guidelines 1. Medical management Switching to atypical antipsychotics: insufficient evidence to support or refute treatment of tardive syndromes by withdrawing causative agents or switching from typical to atypical dopamine receptor blocking agent. I Clonazepam: Consider initiating clonazepam for symptom relief in patients with tardive dyskinesia. C Consider initiating ginkgo biloba for symptom relief in patients with tardive syndromes. C Risperidone: avoid using risperidone as a treatment for tardive syndromes, as neuroleptics may cause tardive syndromes, despite masking symptoms. Amantadine and tetrabenazine: consider amantadine and tetrabenazine as treatments for tardive syndromes. C Agents with no evidence for efficacy: Avoid diltiazem as a treatment for tardive dyskinesia. D Avoid galantamine and eicosapentaenoic acid as treatments for tardive dyskinesia. D https://web.pathway.md/diseases/rechvtiebKXbDcDxs 1/2 6/24/23, 4:05 PM Tardive dyskinesia Pathway References 1. Bhidayasiri R, Fahn S, Weiner WJ et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30;81 5 463 9. Open 2. Bhidayasiri R, Jitkritsadakul O, Friedman JH et al. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018 Jun 15;389 67 75. Open https://web.pathway.md/diseases/rechvtiebKXbDcDxs 2/2